Tscan therapeutics appoints zoran zdraveski, j.d., ph.d. as chief legal officer

Waltham, mass., sept. 09, 2021 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a biopharmaceutical company focused on the development of t-cell receptor (tcr) engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that zoran zdraveski, j.d., ph.d. has been appointed as chief legal officer.
TCRX Ratings Summary
TCRX Quant Ranking